CASI Pharmaceuticals (CASI) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.

Which has preferable earnings & valuation, CASI or FTLF?

FitLife Brands has higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$28.54M	0.84	-$26.94M	-$2.57	-0.76
FitLife Brands	$64.47M	1.76	$5.30M	$0.84	14.62

Does the MarketBeat Community prefer CASI or FTLF?

CASI Pharmaceuticals received 198 more outperform votes than FitLife Brands when rated by MarketBeat users. However, 60.00% of users gave FitLife Brands an outperform vote while only 49.14% of users gave CASI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
CASI Pharmaceuticals	Outperform Votes 201 49.14%	Underperform Votes 208 50.86%
FitLife Brands	Outperform Votes 3 60.00%	Underperform Votes 2 40.00%

Is CASI or FTLF more profitable?

FitLife Brands has a net margin of 13.38% compared to CASI Pharmaceuticals' net margin of -143.18%. FitLife Brands' return on equity of 28.03% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%
FitLife Brands	13.38%	28.03%	15.13%

Which has more volatility & risk, CASI or FTLF?

CASI Pharmaceuticals has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, FitLife Brands has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Do institutionals & insiders believe in CASI or FTLF?

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 2.3% of FitLife Brands shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 61.3% of FitLife Brands shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media prefer CASI or FTLF?

In the previous week, CASI Pharmaceuticals had 7 more articles in the media than FitLife Brands. MarketBeat recorded 9 mentions for CASI Pharmaceuticals and 2 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 0.93 beat CASI Pharmaceuticals' score of 0.42 indicating that FitLife Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
FitLife Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer CASI or FTLF?

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 106.08%. FitLife Brands has a consensus target price of $20.50, suggesting a potential upside of 66.94%. Given CASI Pharmaceuticals' higher possible upside, equities research analysts plainly believe CASI Pharmaceuticals is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
FitLife Brands	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Summary

FitLife Brands beats CASI Pharmaceuticals on 15 of the 19 factors compared between the two stocks.